The company, founded by pioneers of the rapid test industry, has developed a proprietary patented immunoassay platform enabling the development of qualitative and multiplex point of care diagnostics. Results are obtained in few minutes from a single drop of blood (or any other type of sample).

NG Biotech sells a range of CE marked rapid tests Worldwide. Product validations are performed in comparison to laboratory standard reference methods such as Elisa or HPLC. The company is ISO 13485:2016 certified.

Current production capacity is of more than 4 million tests per month.

At NG Biotech we support our partners’ Innovation meeting their screening and monitoring needs; we develop new solutions for their applications. Targeted areas are m-Health, Companion and Medical Diagnostics. We also cover Animal Health, Agriculture and Biodefense among others. We put our know-how and expertise in product development, manufacturing and product registration at your service.

Vision
To become one of the global leaders in rapid tests.

Missions
– NG Biotech develops, manufactures and markets in vitro diagnostics for screening, diagnosis, monitoring and prevention.
– We focus on urgency of decision making processes with rapid and easy to use tests providing quicker support to healthcare professionals and patients.